Open an account

Q32 Bio

QTTB · NASDAQ

$8.62+$0.83 (+10.65%)TodayMarket closed ·
Prev close $7.79

About QTTB

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2018-03-28. The firm is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.

Employees
24
Headquarters
Waltham, Massachusetts
Listed
Mar 28, 2018
Sector
Health Care
Industry
Biotechnology
Website
q32bio.com

QTTB key statistics

Market cap
256.61M
Price-earnings ratio
2.49
Dividend yield
—
Average volume
1.13M
Volume
506.50K
Open price
$7.79
High today
$8.84
Low today
$7.79
52 Week high
$23.57
52 Week low
$1.91

Q32 Bio (QTTB) at a glance

Q32 Bio (QTTB) last traded at $8.62, with a market cap of 256.61M and a price-to-earnings ratio of 2.49.

Today the stock has traded between $7.79 and $8.84. The current price is 10.7% above the day's low and 2.5% below its high.

Volume so far is 506.50K shares, below the average of 1.13M shares a day.

Over the past year Q32 Bio has ranged from $1.91 to $23.57, and now sits 31% of the way up that range.

Q32 Bio met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.43 per share against an estimate of -$0.553.

The average analyst price target is $40.12, 365.4% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $40.12
Low
$29.29
Now
$8.62
High
$61.95

QTTB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 97.9% on average.

  1. Q3 FY24: reported -$1.46 per share against an estimate of -$1.43
  2. Q4 FY24: reported -$1.16 per share against an estimate of -$1.54
  3. Q1 FY25: reported -$0.90 per share against an estimate of -$1.25
  4. Q2 FY25: reported -$0.78 per share against an estimate of -$0.9996
  5. Q3 FY25: reported -$0.60 per share against an estimate of -$1.21
  6. Q4 FY25: reported $3.65 per share against an estimate of -$0.8779
  7. Q1 FY26: reported -$0.54 per share against an estimate of -$0.6936
  8. Q2 FY26: reported -$0.43 per share against an estimate of -$0.553

QTTB news

  • Press releasePRNewswire

    Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

  • Press releasePRNewswire

    Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

  • Press releasePRNewswire

    Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

  • Press releasePRNewswire

    Q32 Bio to Participate in Upcoming September Investor Conferences

  • Press releasePRNewswire

    Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Akanksha Bakshi

    Why Is Q32 Bio Stock Falling Wednesday?

  • Press releasePRNewswire

    Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

  • Press releasePRNewswire

    Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Similar companies

Companies in the same industry as Q32 Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.